Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: Comparative cohort study from BAFTA trial

BMJ

Volumn 343, Issue 7815, 2011, Pages

  Hobbs, F D R ^a   Roalfe, A K ^b   Lip, G Y H ^b   Fletcher, K ^b   Fitzmaurice, D A ^b   Mant, J ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; AGING; ARTICLE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT TOOL; CONGESTIVE HEART FAILURE; CONGESTIVE HEART FAILURE HYPERTENSION AGE 75 YEARS DIABETES PREVIOUS STROKE SCORE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GERIATRIC ASSESSMENT; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMIC DISEASE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; COHORT ANALYSIS; COMPARATIVE STUDY; STROKE;

AGED; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; MALE; STROKE; WARFARIN;

EID: 80355146068     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d3653     Document Type: Article

References (44)

1. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, et al. Mortality trends in patients diagnosed with first atrial fibrillation - a 21-year community study. J Am Coll Cardiol 2007;49:986-92.
2. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice for detection of atrial fibrillation in people aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383-6. (Pubitemid 47359316)
3. Wolf PA, Abbott RD, Kannell WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
4. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;3:CD001927.
5. Koudstaal PJ. Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 1996;1:CD000186.
6. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. (Pubitemid 35340540)
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
8. Van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-43. (Pubitemid 36519739)
9. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-10.
10. Mant J, Wade DT, Winner S. Health care needs assessment: stroke. In: Stevens A, Raftery J, Mant J, Simpson S, eds. Health care needs assessment: the epidemiologically based needs assessment reviews. 1st series. 2nd ed. Radcliffe Medical Press, 2004:141-244.
11. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)
12. Van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FDR, et al. The influence of patient age on the effect of stroke prevention therapy in atrial fibrillation: a secondary analysis of data from randomized trials. Stroke 2009:40:1410-6.
13. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006;37:447-51. (Pubitemid 43732003)
14. Wheeldon NM, Taylor DI, Anagnostou E, Cook D, Wales C, Oakley GDG. Screening for atrial fibrillation in primary care. Heart 1998;79:50-5. (Pubitemid 28179063)
15. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
17. Wang TJ, Massaro JM, Levy D, Vasan RV, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Study. JAMA 2003;290:1049-56. (Pubitemid 37430445)
18. National Institute for Health and Clinical Excellence. Atrial fibrillation: NICE guideline CG36. NICE, 2006:47.
19. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. Circulation 2006;114:e257-354.
20. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114(suppl 5):579-89S.
21. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
22. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008;156:57-64. (Pubitemid 351877101)
23. Lip GYH, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007;6:981-93. (Pubitemid 47566414)
24. Gutierrez RG. Parametric frailty and shared frailty survival models. Stata J 2002;2:22-44.
25. Schoenfeld D. Residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
26. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE, for the ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810-5. (Pubitemid 351253746)
27. National Institute for Health and Clinical Excellence. Atrial fibrillation. The management of atrial fibrillation costing report. NICE, 2006.
28. Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish Primary Care. Stroke 2005;36:1771-5. (Pubitemid 41098777)
29. Burton C, Isles C, Norrie J, Hanson R, Grubb E. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract 2006;56:697-702. (Pubitemid 44390244)
30. Allen LaPointe NM, Governale L, Watkins J, Mulgund J, Anstrom KJ. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. Am Heart J 2007;154:893-8. (Pubitemid 350001279)
31. Laguna P, Martn A, del Arco C, Gargantilla P, Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group (GEFAUR). Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann Emerg Med 2004;44:3-11. (Pubitemid 38864784)
32. Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006;97:538-43. (Pubitemid 43190046)
33. Dubhghaill CT, Moonen L, O'Loughlin A, O'Keeffe S, Egan D, Murphy AW. Implementation of anticoagulation guidelines in general practice: a practice report. Ir Med J 2003;96:296-9.
34. Pradhan AA, Levine MA. Warfarin use in atrial fibrillation: a random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol 2002;9:199-202.
35. Rutten FH, Hak E, Stalman WA, Verheij TJ, Hoes AW. Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment? Fam Pract 2003;20:16-21. (Pubitemid 36163779)
36. Savage M, Teeling M, Bennett K, Feely J. Adherence to clinical guidance in the prescribing of oral antithrombotic medication in patients with atrial fibrillation. Ir J Med Sci 2006;175:46-9. (Pubitemid 44043788)
37. Partington SL, Abid S, Teo K, Oczkowski W, O'Donnell MJ. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res 2007;120:663-9. (Pubitemid 47271911)
38. Lip GYH, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47:285-9. (Pubitemid 27208108)
39. Gudmundsdottir IJ, Helgason KO, Sigurdsson EL, Arnar DO. Use of warfarin anticoagulation in patients with atrial fibrillation in Iceland. Laeknabladid 2002;88:299-303.
40. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006;27:1954-64. (Pubitemid 44297370)
41. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151-6. (Pubitemid 38869075)
42. Connolly S, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2010:361:1139-51.
43. Gensch C, Hoppe U, Böhm M, Laufs U. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol 2011;100:1-9.
44. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Axipiban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.